Omeros is no longer primarily a regulatory story. That phase changed materially on December 23, 2025, when the FDA approved YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and pediatric patients aged two and older. From that point forward, the central question stopped being “can they get this approved?” and became “can they turn a highly specialized approval into durable commercial traction inside a very concentrated transplant market?”

Milestone Pharmaceuticals is no longer the same equity story it was in the second half of 2025. For months, the stock traded primarily as a regulatory event setup tied to the resubmitted U.S. application for etripamil in paroxysmal supraventricular tachycardia, or PSVT. That phase ended on December 12, 2025, when the FDA approved CARDAMYST, the company’s first commercial product, as a self-administered nasal spray for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. Since that moment, the question has changed completely. The market is no longer asking whether Milestone can get approved. It is asking whether Milestone can launch, obtain access, build prescription momentum, sustain funding discipline, and then extend the same franchise into atrial fibrillation with rapid ventricular rate, or AFib-RVR.

English Italiano RARE DISEASES · HAE · EARNINGS · FRANCHISE EXPANSION BioCryst after the transition: why BCRX is no longer just an ORLADEYO story, and why the next leg depends on execution BioCryst is not the same company the market…

ProKidney’s FY 2025 release did not deliver a dramatic twist, and that is exactly why it matters. Investors were not looking for revenue, because there is none. They were not looking for normal operating leverage, because this is still a pre-commercial biotech. What they needed to see was whether the company could still credibly defend the bridge from today’s balance sheet to the one milestone that truly matters, the Q2 2027 Phase 3 eGFR-slope readout in PROACT 1. For now, the answer remains yes.

SeaStar Medical goes into its March 25, 2026 earnings date with a story that is more credible medically than it was a few months ago, but not yet more comfortable financially. That distinction matters. In ultra-small medtech and biotech names, better clinical framing can improve perception, but it does not automatically repair a pressured capital structure. SeaStar’s recent updates created a more solid pediatric narrative around QUELIMMUNE, yet the company still faces the far more difficult question of whether that narrative can become durable adoption, durable funding and a less fragile 2026 outlook.

Geron’s latest earnings did not kill the bullish case and did not fully validate it either. What they did was more useful: they forced the story into a more serious phase, where commercial consistency, spending discipline and the coming IMpactMF readout matter more than launch excitement.

Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18, 2026, with $51.8 million in revenues from selling goods, $52.7 million in total revenues, and a net loss of $6.6 million. The most important near-term development was not just the annual print itself, but the combination of that print with the European Commission approval of the every-four-weeks dosing regimen for Elfabrio, which triggered a $25 million milestone payment from Chiesi.

I deliberately waited at least one full day before writing this piece. Not to stall, but to look at the March 17, 2026 Complete Response Letter with a colder head, outside the immediate chaos of the tape. What follows is not a quick reaction article. It is a long-form reconstruction of how Aldeyra reached a third rejection in dry eye disease, why that matters far beyond one bad headline, where management deserves a tougher standard, and whether any credible path still exists for reproxalap in DED.